| Li, Xin |
| Active, not recruiting | 4 | 948 | Europe, Canada, US, RoW | Edoxaban, Lixiana, Savaysa, Non-anticoagulant medical therapy | Population Health Research Institute | Intracranial Hemorrhages, Atrial Fibrillation | 04/26 | 10/26 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT04025164: Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery |
|
|
| Recruiting | 3 | 4052 | RoW | Hypofractionated Radiotherapy, Experimental Arm, Conventional fractionated Radiotherapy, Standard Arm | Fudan University | Breast Cancer | 06/23 | 06/28 | | |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Recruiting | 2 | 120 | RoW | TQH3906 capsules, Placebo of TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Plaque Psoriasis | 01/25 | 09/25 | | |
NCT06601504: Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL |
|
|
| Recruiting | 2 | 60 | RoW | HMPL-760 planned dose 1, R-GemOx, Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection, HMPL-760 placebo planned dose 1, HMPL-760 planned dose 2, HMPL-760 placebo planned dose 2 | Hutchmed | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 05/26 | 11/26 | | |
NCT05768529: Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 1/2 | 100 | RoW | U16 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Relapsed or Refractory Non-Hodgkin's Lymphoma | 12/24 | 12/26 | | |
NCT04673799: Comparing of the Pharmacokinetics, Immunogenicity and Safety of MV088 and Prolia® in Healthy Adults. |
|
|
| Not yet recruiting | 1 | 144 | NA | MV088 injection, Prolia® injection | Kunming Pharmaceuticals, Inc. | Healthy | 10/21 | 10/21 | | |
| Completed | 1 | 100 | RoW | AK104 (before the change), AK104 (after the change) | Akeso | Healthy Male Subjects | 03/23 | 04/23 | | |
NCT05758428: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects |
|
|
| Completed | 1 | 28 | RoW | Ensifentrine, Placebo | Nuance Pharma (shanghai) Co., Ltd | Chronic Obstructive Pulmonary Disease | 04/23 | 04/23 | | |
GNC-035-103, NCT05160545: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 1 | 29 | RoW | GNC-035 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer | 06/25 | 12/25 | | |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
NCT05505812: Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer |
|
|
| Not yet recruiting | 1 | 10 | RoW | HS-IT101 | The Affiliated Hospital of Qingdao University, Qingdao Sino-Cell Biomedicine Co.,Ltd. | Breast Cancer | 12/23 | 03/27 | | |
| Not yet recruiting | 1 | 12 | RoW | NTQ5082 capsule | Nanjing Chia-tai Tianqing Pharmaceutical | Complement-mediated Hemolytic Diseases | 12/24 | 02/25 | | |
NCT06560593: A Phase 1 Clinical Trial of NTQ5082 in Healthy Volunteers |
|
|
| Not yet recruiting | 1 | 82 | RoW | NTQ5082, Placebo | Nanjing Chia-tai Tianqing Pharmaceutical | Complement-mediated Hemolytic Diseases | 12/24 | 02/25 | | |
NCT06196060: Improving ToM in Children With ASD Through VPT Training: Behavioral and fNIRS Study |
|
|
| Recruiting | N/A | 100 | RoW | Visual perspective taking training, Block building training, Thought-bubble training, Treatment as usual | Nanjing Normal University, Zhuhai Fudan Innovation Institute, Second Affiliated Hospital of Guangxi Medical University | Autism Spectrum Disorder | 06/24 | 09/24 | | |
NCT06579976: Multimodal High-frequency Ultrasound-based Study of Plaque Psoriasis Severity Index |
|
|
| Not yet recruiting | N/A | 45 | RoW | No intervention | Shanghai Yueyang Integrated Medicine Hospital | Plaque Psoriasis | 02/25 | 05/25 | | |
NCT05665010: Precise Stratification of Genetic Risk of Ovarian Function Impairment |
|
|
| Recruiting | N/A | 1000 | RoW | Genetic susceptibility | Tongji Hospital | Premature Ovarian Insufficiency, Diminished Ovarian Reserve, Early Menopause | 10/23 | 10/24 | | |
| Zhou, Jin |
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC |
|
|
| Recruiting | 2 | 60 | RoW | HLX07+HLX10+ Cisplatin+5-FU, HLX07 | Shanghai Henlius Biotech | ESCC or Esophageal Adenosquamous Carcinoma | 06/24 | 08/25 | | |
| Recruiting | 2 | 270 | RoW | TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-Small Cell Lung Cancer | 10/25 | 02/26 | | |
NCT06753747: A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 1/2 | 45 | RoW | Palbociclib, Afatinib(30mg), Afatinib(40mg), Afatinib(RP2D) | West China Hospital | Esophagus Cancer | 04/27 | 04/28 | | |
NCT06225921: Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas |
|
|
| Recruiting | 1 | 6 | RoW | Adebrelimab, Dalpiciclib 100mg, Dalpiciclib 150mg | West China Hospital | Esophageal Squamous Cell Carcinoma | 01/25 | 01/25 | | |
NCT06654297: Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas |
|
|
| Recruiting | 1 | 6 | RoW | Camrelizumab, Palbociclib(100mg), Palbociclib(125mg) | West China Hospital | Esophageal Squamous Cell Carcinoma | 10/25 | 10/25 | | |
NCT06109207: Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas |
|
|
| Recruiting | 1 | 6 | RoW | Camrelizumab, Dalpiciclib 100mg, Dalpiciclib 150mg | West China Hospital | Head and Neck Squamous Cell Carcinoma | 10/24 | 10/25 | | |
| Sui, Yi |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
NCT05745259: Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ） |
|
|
| Recruiting | 3 | 1630 | RoW | Alteplase, rt-PA, Tenecteplase, TNK-tPA | Beijing Tiantan Hospital, Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd, The Place Pharmaceutical(Jiangsu) Co., Ltd | Acute Ischemic Stroke | 11/23 | 03/24 | | |
SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Shuxuening Injection, Placebo | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 06/25 | 12/26 | | |
TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 12/25 | 12/26 | | |
Mild-MT, NCT06464731: Endovascular Treatment for Mild Ischemic Stroke Due to Acute Large Vessel Occlusion in the Anterior Circulation |
|
|
| Recruiting | N/A | 200 | RoW | EVT, Experimental | Wen-huo Chen | Endovascular Treatment, Mild Stroke | 09/24 | 12/24 | | |
| Recruiting | N/A | 10254 | RoW | | Limeng Chen | Chronic Kidney Diseases, Chronic Kidney Disease-Mineral and Bone Disorder | 12/24 | 12/24 | | |
DISCO, NCT06507488: Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia |
|
|
| Not yet recruiting | N/A | 206 | RoW | Daphnetin Capsule, 7,8-dihydroxycoumarin, Placebo | First People's Hospital of Shenyang | Cerebrovascular Disorders | 12/25 | 04/26 | | |
| Recruiting | N/A | 7200 | Europe, US, RoW | Low-intensity monitoring strategy, Guideline recommended standard monitoring | Craig Anderson, Genentech, Inc., Johns Hopkins University, The George Institute for Global Health, Australia | Acute Ischemic Stroke Patients Receiving Reperfusion Therapy | 11/24 | 03/25 | | |
NCT05988125: Prospective Registry Study of Endovascular Treatment for Acute Ischemic Stroke Patients |
|
|
| Recruiting | N/A | 2000 | RoW | | Tingyu-Yi, Fujian Medical University Union Hospital, The First Affiliated Hospital of Nanchang University, First People's Hospital of Shenyang | Endovascular Treatment | 12/24 | 03/25 | | |
NCT04157231: Essential Acute Stroke Care in Low Resource Settings: a Pilot studY |
|
|
| Not yet recruiting | N/A | 300 | RoW | Acute stroke care Intervention arm | The George Institute, World Heart Federation | Acute Stroke | 10/25 | 11/25 | | |
| Sui, Tie |
NCT06322394: BXOS110 Injection in the Treatment of Acute Ischaemic Stroke |
|
|
| Recruiting | 2 | 300 | RoW | high-dose BXOS110, BXOS110, low-dose BXOS110, Placebo | Biocells (Beijing) Biotech Co.,Ltd | Acute Ischemic Stroke | 03/25 | 09/25 | | |
| Yi, Sui |
NCT06315231: Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients |
|
|
| Recruiting | 2 | 200 | RoW | Edaravone dexborneol sublingual tablet, Placebo | Simcere Pharmaceutical Co., Ltd | Post-stroke Cognitive Impairment | 12/26 | 12/26 | | |
